Optimi Health Expands to NZ with Psilocybin Trial

Optimi Health Corp. (TSE:OPTI) has released an update.

Optimi Health Corp., a Canadian licensed producer of psychedelics, has announced a landmark supply agreement with New Zealand’s Mātai Medical Research Institute to provide its GMP Full Spectrum Natural Psilocybin extract for a pioneering clinical trial. The venture signifies Optimi’s entry into the New Zealand market and will support a study on the use of psilocybin in a traditional Māori setting. This trial is a first of its kind, intending to blend modern psychedelic-assisted therapy with indigenous cultural practices.

For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.